Summary
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
Register to download
Human Abuse Liability Studies: Not Your Traditional Phase I Study
You may also be interested in:
Infographic
Alzheimers Disease Infographic
Alzheimer's Disease is the most common type of dementia accounting for 60%-80% of all cases. In the past 5 years, PRA has conducted numerous clinical…
Capability
Pain Studies at PRA Early Development Services
PRA Health Sciences offers a range of pain models to assess pain perception and the efficacy of experimental analgesics in healthy volunteers and…
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…